IGC Pharma (IGC) Price to Sales (2010 - 2025)

IGC Pharma (IGC) has reported Price to Sales for 16 consecutive years, with 200.72 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Price to Sales rose 152.77% year-over-year to 200.72 in Q3 2025; TTM through Sep 2025 was 26.7, a 3.46% decrease from a year earlier, with the FY2026 full-year figure at 81.97, up 351.97% from the prior year.
• Price to Sales was 200.72 for Q3 2025 at IGC Pharma, up from 39.13 in the prior quarter.
• Over five years, Price to Sales peaked at 1348.94 in Q3 2021 and troughed at 29.8 in Q2 2023.
• A 5-year average of 288.58 and a median of 108.55 in 2023 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales surged 2333.81% in 2021 and tumbled 91.6% in 2022, its largest moves.
• Over 5 years, Price to Sales stood at 351.09 in 2021, then slumped by 85.51% to 50.86 in 2022, then surged by 72.08% to 87.51 in 2023, then increased by 16.84% to 102.24 in 2024, then jumped by 96.32% to 200.72 in 2025.
• The last three Price to Sales figures came in at 200.72 (Q3 2025), 39.13 (Q2 2025), and 69.85 (Q1 2025), per Business Quant data.